Effect of Single Oral Dose of Vitamin D in Primary Dysmenorhea

Improvement of Primary Dysmenorrhea Caused by a Single Oral Dose of Vitamin D: Results of a Randomized, Double-blind, Placebo-Controlled Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013022312582N1

Enrollment

Registered

2013-08-18

Start date

2012-11-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: primary dysmenorhea. Condition 2: Vitamin D deficiency. Primary dysmenorrhoea Vitamin D deficiency, unspecified

Interventions

Intervention 1: The intervention group received a single oral dose of cholecalciferol (300 000 IUs) 5 days before the putative beginning of their next menstrual cycle and NSAIDs. Intervention 2: The

Treatment - Drugs

The intervention group received a single oral dose of cholecalciferol (300 000 IUs) 5 days before the putative beginning of their next menstrual cycle and NSAIDs.

The Placebo group received a placebo drug cholecalciferol 5 days before the putative beginning of their next menstrual cycle and NSAIDs.

Eligibility

Sex/Gender

Female

Age

18 Years to 30 Years

Inclusion criteria

Inclusion criteria: Inclution Criterias :Their menstrual cycles lasted 21 to 35 days; With menstruation lasting 3 to 7 days; They experienced at least 4 consecutive painful periods in the past 6 months with the pain starting one day before or on the day of onset of bleeding; They showed a 25(OH)D serum level; Patients had to be in good health and taking no medications including calcium, vitamin D, and oral contraceptives;Sonografy of ovary and utrian is normal in the past 6 months. Exclutios Criteria: Had no Their menstrual cycles lasted 21 to 35 days;had no With menstruation lasting 3 to 7 days; They no experienced at least 4 consecutive painful periods in the past 6 months with the pain starting one day before or on the day of onset of bleeding; Patients had no be in good health and taking medications including calcium, vitamin D, and oral contraceptives; Sonografy of ovary and utrian is abnormal in the past 6 months.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The intensity of menstrual pain. Timepoint: before, 1 and 3 months after intervention. Method of measurement: visual analogue scale(VAS).	—

Secondary

Measure	Time frame
Use of NSAIDs. Timepoint: before, 1 and 3 months after intervention. Method of measurement: asking from subjects.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMina Ataee

Kermanshah University of Medical Sciences and Research

ataee.mina@yahoo.comm.zangene.59710@yahoo.comjalal_re@yahoo.com+98 83 1838 4158

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026